Search

Search Bar
01/12/2022 Conducting clinical trials in persons with Down syndrome: summary from the NIH INCLUDE Down syndrome clinical trials readiness working group
Baumer, NT, Becker, ML, Capone, GT, Egan, K, Fortea, J, Handen, BL, Head, E, Hendrix, JE, Litovsky, RY, Strydom, A, Tapia, IE, Rafii, MS. Conducting clinical trials in persons with Down syndrome: summary from the NIH INCLUDE Down syndrome clinical trials readiness working group. Journal of Neurodevelopmental Disorders. 2022; 14(1)DOI:10.1186/s11689-022-09435-z. PMID:35321660. IF:4.900(Q1/3D).
27/06/2022 Importance of cerebrospinal fluid storage conditions for the Alzheimer's disease diagnostics on an automated platform
Ferrer, R, Zhu, N, Arranz, J, Porcel, I, El Bounasri, S, Sanchez, O, Torres, S, Julve, J, Lleo, A, Blanco-Vaca, F, Alcolea, D, Tondo, M. Importance of cerebrospinal fluid storage conditions for the Alzheimer's disease diagnostics on an automated platform. CLINICAL CHEMISTRY AND LABORATORY MEDICINE. 2022; 60(7)DOI:10.1515/cclm-2022-0134. PMID:35405043. IF:6.800(Q1/2D).
13/05/2022 Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease (vol 17, pg 1, 2022)
Visser, PJ, Reus, LM, Gobom, J, Jansen, I, Dicks, E, van der Lee, SJ, Tsolaki, M, Verhey, FRJ, Popp, J, Martinez-Lage, P, Vandenberghe, R, Lleo, A, Molinuevo, JL, Engelborghs, S, Freund-Levi, Y, Froelich, L, Sleegers, K, Dobricic, V, Lovestone, S, Streffer, J, Vos, SJB, Bos, I, Smit, AB, Blennow, K, Scheltens, P, Teunissen, CE, Bertram, L, Zetterberg, H, Tijms, BM. Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease (vol 17, pg 1, 2022). Molecular Neurodegeneration. 2022; 17(1)DOI:10.1186/s13024-022-00540-0. PMID:35550177. IF:15.100(Q1/1D).
29/04/2022 Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration
Illan-Gala, I, Nigro, S, VandeVrede, L, Falgas, N, Heuer, HW, Painous, C, Compta, Y, Marti, MJ, Montal, V, Pagonabarraga, J, Kulisevsky, J, Lleo, A, Fortea, J, Logroscino, G, Quattrone, A, Quattrone, A, Perry, DC, Gorno-Tempini, ML, Rosen, HJ, Grinberg, LT, Spina, S, La Joie, R, Rabinovici, GD, Miller, BL, Rojas, JC, Seeley, WW, Boxer, AL. Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration. JAMA Network Open. 2022; 5(4)DOI:10.1001/jamanetworkopen.2022.9588. PMID:35486397. IF:13.800(Q1/1D).
26/04/2022 Genotype-Phenotype Correlation in Progressive Supranuclear Palsy Syndromes: Clinical and Radiological Similarities and Specificities
Ruiz-Barrio, I, Horta-Barba, A, Illan-Gala, I, Kulisevsky, J, Pagonabarraga, J. Genotype-Phenotype Correlation in Progressive Supranuclear Palsy Syndromes: Clinical and Radiological Similarities and Specificities. Frontiers in Neurology. 2022; 13DOI:10.3389/fneur.2022.861585. PMID:35557621. IF:3.400(Q2/5D).
08/04/2022 Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration
Gonzalez, AC, Irwin, DJ, Alcolea, D, McMillan, CT, Chen-Plotkin, A, Wolk, D, Sirisi, S, Dols-Icardo, O, Querol-Vilaseca, M, Illan-Gala, I, Santos-Santos, MA, Fortea, J, Lee, EB, Trojanowski, JQ, Grossman, M, Lleo, A, Belbin, O. Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration. Molecular Neurodegeneration. 2022; 17(1)DOI:10.1186/s13024-022-00534-y. PMID:35395770. IF:15.100(Q1/1D).